Evaluating the Safety and Potential Efficacy of Platelet-Rich Plasma (PRP) Therapy in Patients with Detrusor Underactivity (DUA)

A Single-Arm Feasibility Study Evaluating the Safety and Potential Efficacy of Platelet-Rich Plasma (PRP) Therapy in Patients with Detrusor Underactivity (DUA) - nil

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/091024

Enrollment

Registered

2025-07-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: N318- Other neuromuscular dysfunction ofbladder

Interventions

Intervention1: platelet rich plasma(PRP): Platelet rich plasma(PRP)from patients own blood. Intervention2: PRP platelet rich plasma: Patients own platelet rich plasma after activation with calcium chl

Eligibility

Inclusion criteria

Inclusion criteria: Patients of detrusor underactivity

Exclusion criteria

Exclusion criteria: Exclusion Criteria Active urinary tract infection Bladder malignancy Coagulopathy or platelet dysfunction disorders Pregnancy

Design outcomes

Primary

Measure	Time frame
Primary Outcomes: Improvement in detrusor contractility (measured as PdetMax maximum detrusor pressure on urodynamics) Reduction in post-void residual (PVR) volume (mL) by MSCD/minimal significant clinical difference of at least 10% over previous value. Timepoint: measured at 1, 3, 6, and 12 months.	—

Secondary

Measure	Time frame
Improvement in patient reported symptoms (IPSS, VAS) MSCD/minimal significant clinical difference of at least 2 points in IPSS & one in VAS. - Reduction in catheterization frequency by at least 2 . - Improvement in bladder compliance & Qmax (uroflowmetry) MSCD/minimal significant clinical difference of at least by 2 points Timepoint: Patient reported outcome measures (IPSS, VAS, QoL) At 1, 3, 6, & 12 months	—

Measure

Time frame

Improvement in patient reported symptoms (IPSS, VAS) MSCD/minimal significant clinical difference of at least 2 points in IPSS & one in VAS. - Reduction in catheterization frequency by at least 2 . - Improvement in bladder compliance & Qmax (uroflowmetry) MSCD/minimal significant clinical difference of at least by 2 points Timepoint: Patient reported outcome measures (IPSS, VAS, QoL) At 1, 3, 6, & 12 months

—

Countries

India

Contacts

Public ContactSatyadeo Sharma

All India Institute of Medical Sciences Raipur

satyadeo2004@gmail.com7772967744

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026